-
Something wrong with this record ?
The Central Effects of Botulinum Toxin in Dystonia and Spasticity
P. Hok, T. Veverka, P. Hluštík, M. Nevrlý, P. Kaňovský
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Grant support
NV16-30210A; NV17-29452A
Ministerstvo Zdravotnictví Ceské Republiky
NLK
Directory of Open Access Journals
from 2009
Free Medical Journals
from 2009
PubMed Central
from 2009
Europe PubMed Central
from 2009
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Medline Complete (EBSCOhost)
from 2010-09-01
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2009
- MeSH
- Botulinum Toxins, Type A adverse effects therapeutic use MeSH
- Dystonia diagnosis drug therapy physiopathology MeSH
- Muscle, Skeletal innervation MeSH
- Humans MeSH
- Magnetic Resonance Imaging MeSH
- Brain Mapping MeSH
- Cerebral Cortex diagnostic imaging drug effects physiopathology MeSH
- Neuromuscular Agents adverse effects therapeutic use MeSH
- Neuronal Plasticity drug effects MeSH
- Recovery of Function MeSH
- Motor Activity drug effects MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
In dystonic and spastic movement disorders, however different in their pathophysiological mechanisms, a similar impairment of sensorimotor control with special emphasis on afferentation is assumed. Peripheral intervention on afferent inputs evokes plastic changes within the central sensorimotor system. Intramuscular application of botulinum toxin type A (BoNT-A) is a standard evidence-based treatment for both conditions. Apart from its peripheral action on muscle spindles, a growing body of evidence suggests that BoNT-A effects could also be mediated by changes at the central level including cerebral cortex. We review recent studies employing electrophysiology and neuroimaging to investigate how intramuscular application of BoNT-A influences cortical reorganization. Based on such data, BoNT-A becomes gradually accepted as a promising tool to correct the maladaptive plastic changes within the sensorimotor cortex. In summary, electrophysiology and especially neuroimaging studies with BoNT-A further our understanding of pathophysiology underlying dystonic and spastic movement disorders and may consequently help develop novel treatment strategies based on neural plasticity.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026068
- 003
- CZ-PrNML
- 005
- 20211026133231.0
- 007
- ta
- 008
- 211013s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/toxins13020155 $2 doi
- 035 __
- $a (PubMed)33671128
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Hok, Pavel $u Department of Neurology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacký University Olomouc, 779 00 Olomouc, Czech Republic
- 245 14
- $a The Central Effects of Botulinum Toxin in Dystonia and Spasticity / $c P. Hok, T. Veverka, P. Hluštík, M. Nevrlý, P. Kaňovský
- 520 9_
- $a In dystonic and spastic movement disorders, however different in their pathophysiological mechanisms, a similar impairment of sensorimotor control with special emphasis on afferentation is assumed. Peripheral intervention on afferent inputs evokes plastic changes within the central sensorimotor system. Intramuscular application of botulinum toxin type A (BoNT-A) is a standard evidence-based treatment for both conditions. Apart from its peripheral action on muscle spindles, a growing body of evidence suggests that BoNT-A effects could also be mediated by changes at the central level including cerebral cortex. We review recent studies employing electrophysiology and neuroimaging to investigate how intramuscular application of BoNT-A influences cortical reorganization. Based on such data, BoNT-A becomes gradually accepted as a promising tool to correct the maladaptive plastic changes within the sensorimotor cortex. In summary, electrophysiology and especially neuroimaging studies with BoNT-A further our understanding of pathophysiology underlying dystonic and spastic movement disorders and may consequently help develop novel treatment strategies based on neural plasticity.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a botulotoxiny typu A $x škodlivé účinky $x terapeutické užití $7 D019274
- 650 _2
- $a mapování mozku $7 D001931
- 650 _2
- $a mozková kůra $x diagnostické zobrazování $x účinky léků $x patofyziologie $7 D002540
- 650 _2
- $a dystonie $x diagnóza $x farmakoterapie $x patofyziologie $7 D004421
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a pohybová aktivita $x účinky léků $7 D009043
- 650 _2
- $a kosterní svaly $x inervace $7 D018482
- 650 _2
- $a nervosvalové látky $x škodlivé účinky $x terapeutické užití $7 D009465
- 650 _2
- $a neuroplasticita $x účinky léků $7 D009473
- 650 _2
- $a obnova funkce $7 D020127
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Veverka, Tomáš $u Department of Neurology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacký University Olomouc, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Hluštík, Petr $u Department of Neurology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacký University Olomouc, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Nevrlý, Martin $u Department of Neurology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacký University Olomouc, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Kaňovský, Petr $u Department of Neurology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacký University Olomouc, 779 00 Olomouc, Czech Republic
- 773 0_
- $w MED00177194 $t Toxins $x 2072-6651 $g Roč. 13, č. 2 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33671128 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133237 $b ABA008
- 999 __
- $a ok $b bmc $g 1714934 $s 1146575
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 13 $c 2 $e 20210217 $i 2072-6651 $m Toxins $n Toxins $x MED00177194
- GRA __
- $a NV16-30210A; NV17-29452A $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20211013